In last trading session, Zenas Biopharma Inc (NASDAQ:ZBIO) saw 0.49 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $9.58 trading at -$0.57 or -5.62% at ring of the bell on the day assigns it a market valuation of $400.77M. That closing price of ZBIO’s stock is at a discount of -174.01% from its 52-week high price of $26.25 and is indicating a premium of 39.14% from its 52-week low price of $5.83. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.18 million shares which gives us an average trading volume of 184.45K if we extend that period to 3-months.
Zenas Biopharma Inc (NASDAQ:ZBIO) trade information
Upright in the red during last session for losing -5.62%, in the last five days ZBIO remained trading in the green while hitting it’s week-highest on Thursday, 06/26/25 when the stock touched $9.58 price level, adding 11.95% to its value on the day. Zenas Biopharma Inc (NASDAQ:ZBIO) showed a performance of 3.79% in past 30-days. Number of shares sold short was 4.91 million shares which calculate 26.69 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 35 to the stock, which implies a rise of 72.63% to its current value. Analysts have been projecting 35 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -265.34% in reaching the projected high whereas dropping to the targeted low would mean a loss of -265.34% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 65.55% while estimates for its earnings growth in next 5 years are of 31.82%.
Zenas Biopharma Inc (NASDAQ:ZBIO)’s Major holders
Insiders are in possession of 21.20% of company’s total shares while institution are holding 74.88 percent of that, with stock having share float percentage of 95.02%. Investors also watch the number of corporate investors in a company very closely, which is 74.88% institutions for Zenas Biopharma Inc that are currently holding shares of the company.
